Navigation Links
Radiation Oncology Institute Campaign Raises $3 Million
Date:9/10/2008

Varian Medical Systems pledges $2 million toward $10 million campaign goal

FAIRFAX, Va., Sept. 10 /PRNewswire-USNewswire/ -- The newly formed Radiation Oncology Institute has so far raised $3 million as part of its initial campaign goal and is on target to achieve its $10 million initial campaign goal.

Following an initial commitment of $5 million from the American Society for Therapeutic Radiology and Oncology -- $3 million of which is a challenge grant to ASTRO members, individual radiation oncologists have done their part by pledging nearly $1 million in commitments to date. With the critical mass pledged by the physicians and radiation therapy treatment team members, industry partners were invited to join the campaign as well. Radiation therapy equipment manufacturer Varian did so with a leadership commitment of $2 million.

"We all know that radiation therapy is one of the most powerful weapons available to patients fighting cancer, particularly in light of advances made in the last 10 years. Radiation therapy is not only clinically effective, it is cost effective, too," said Timothy E. Guertin, CEO of Varian Medical Systems in Palo Alto, Calif. "The problem is that the rest of the world doesn't seem to get it. Many patients, members of the public, referring physicians, surgical and medical oncologists, and policy makers continue to think of radiation as a therapy of last resort, rather than a therapy to be preferred. We are excited to be a part of ROI since its goals are to improve the position and standing of radiation oncology and demonstrate the value and clinical benefits that this important treatment brings to improve and extend the lives of cancer patients every day."

"Our plan is for ROI to conduct objective research on the specialty to document the value, safety, efficacy and cost effectiveness of radiation therapy with the goal of 'stepping up' the profile of radiation therapy within the medical community to ensure that cancer patients have access to the treatments that are best for them, their lifestyle and their cancer," said Campaign Co-chair Colleen A. Lawton, M.D., FASTRO, from the Medical College of Wisconsin in Milwaukee. "It is gratifying to see so many of my physician colleagues as well as Varian step up to support this exciting initiative."

"I am excited that so many of my colleagues believe in the vision of ROI to develop open, objective research that will demonstrate the value that radiation oncology brings to cancer care throughout the world," said Campaign Co-chair Theodore S. Lawrence, M.D., Ph.D., FASTRO, from the University of Michigan in Ann Arbor, Mich.

For more information on ROI, including a list of donors and information on contributing, please visit http://www.roinstitute.org.

The Radiation Oncology Institute was established to develop innovative ways of enhancing the profile of radiation oncology in the world cancer community and prepare the specialty for the future. For more information, visit http://www.roinstitute.org.


'/>"/>
SOURCE American Society for Therapeutic Radiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Informational handout key to giving parents a better understanding of CT radiation risks
2. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
3. Different method of evaluating the urinary tract system reduces radiation dose
4. Radiation and drug combo helps boost efficacy of lung cancer treatment
5. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
6. Radiation therapy technique reduces length of prostate cancer treatment
7. Radiation therapy technique reduces length of prostate cancer treatment
8. Jefferson radiation oncologists use real-time system to plant seeds against cancer
9. Radiation Therapy Services Acquires North Carolina Facility
10. NASA, NSBRI Select 17 Proposals in Space Radiation Research
11. Breast Cancer Radiation Wont Hurt Immune Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... of the Best Places to Work in the Research Triangle for 2017. , ... nominated, a company had to meet a threshold in employee participation--a percentage that ...
(Date:9/20/2017)... ... 2017 , ... Demand generation pioneer True Influence has announced ... The Marketing Tech Conference October 2–4, at the Hynes Convention Center in Boston, ... representing such thought-leading companies as JP Morgan Chase, GE Digital, and Dun & ...
(Date:9/20/2017)... ... ... In just a short time since going on sale on Wal-Mart Stores-owned ... trying the product for the first time, and others who had already been using ... Moore, MD, for everyone from athletes at risk from multiple concussions to elderly consumers ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) ... HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, 2017 to assist ... offering these discounted prices to all businesses and government agencies – whether or not ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm ... Friday, September 8, and Monday, September 11, off work and rolled up their sleeves ... before heading to local homes to start the process of rebuilding. , CORDA founder ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
Breaking Medicine Technology: